1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -5.76M | 8.44% |
| EBITDA | -5.85M | 4.25% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.72M |
Number of shares | 2.04M |
52-week high/low | €12.36 - €3.56 |
| Dividends | No |
Beta | 1.76 |
P/E ratio | -0.80 |
PEG ratio | 0.04 |
P/B ratio | 1.14 |
P/S ratio | 73.48 |
Company profile
Diffusion Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das neuartige Therapien entwickelt, die die Fähigkeit des Körpers zur Sauerstoffversorgung verbessern. Der führende Produktkandidat ist Trans-Natrium-Crocetinat, das zur Verbesserung der Sauerstoffdiffusion in das Gewebe und zur Behandlung der COVID-19-Krankheit entwickelt wird. Diffusion Pharmaceuticals Inc. wurde im Jahr 2001 gegründet und hat seinen Sitz in Charlottesville, Virginia.
| Name | Diffusion Pharma |
| CEO | Robert J. Cobuzzi Jr., |
| Headquarters | Charlottesville,
va USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/23/2008 |
| Employees | 13 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | DFFN |
Discover assets
Shareholders of Diffusion Pharma also invest in the following assets
